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Summary Community-based screening and treatment of women age 70–85 years at high 
fracture risk reduced fractures; moreover, the screening programme of fracture risk in older 
women had an effect that was cost-saving. The results support a case for a screening 
programme of fracture risk in older women in the UK. 
Purpose The SCOOP (screening for prevention of fractures in older women) randomised 
controlled trial investigated whether community-based screening could reduce fractures in 
women age 70–85 years. The objective of this study was to estimate the long-term cost-
effectiveness of screening for fracture risk in a UK primary care setting compared with usual 
management, based on the SCOOP study. 
Methods A health economic Markov model was used to predict the life-time consequences in 
terms of costs and quality of life of the screening programme compared with the control arm. 
The model was populated with costs related to drugs, administration and screening 
intervention derived from the SCOOP study. Fracture risk reduction in the screening arm 
compared with the usual management arm was derived from SCOOP. Modelled fracture risk 
corresponded to the risk observed in SCOOP.  
Results Screening saved 9 hip fractures and 20 non-hip fractures over the remaining lifetime 
(mean 14 years) of 1,000 patients compared with usual management. In total, the screening 
arm saved costs (£286) and gained 0.015 QALYs/patient in comparison with usual 
management arm.  
Conclusions This analysis suggests that a screening programme of fracture risk in older 
women in the UK would gain quality of life and life years, and reduce fracture costs to more 
than offset the cost of running the programme. 
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It is estimated that over 500,000 fragility fractures were sustained in the UK in 2010 [1]. 
Fragility fractures are associated with major societal costs and individual suffering. In 2010, 
the monetary burden of osteoporosis was £4,397 million in the UK, the majority of which was 
costs related to treating fractures. In addition, approximately 160,000 QALYs were lost in the 
same year due to incident and previous fractures. Although many available treatments for 
fracture prevention have been shown to be cost-effective in patients at high risk of fracture 
[2], there is a large “treatment gap”, in that a minority of individuals at high fracture risk are 
identified and receive appropriate treatment [3]. 
Historically, fracture risk has been assessed mainly by the use of bone mineral density (BMD) 
measurement alone. BMD has been shown, however, to have low sensitivity for fracture risk 
in that most fragility fractures arise in individuals without densitometric osteoporosis [4]. 
FRAX® is a tool freely accessible on the web (www.shef.ac.uk/FRAX), which was developed to 
improve the prediction of fracture risk [5]. FRAX calculates the 10-year hip and major 
osteoporotic fracture probabilities based on a set of clinical risk factors and is recommended, 
for example, by the National Institute for Health and Care Excellence (NICE) and the National 
Osteoporosis Guidelines Group (NOGG) for the assessment of patients in the UK [6, 7]. NOGG 
also uses FRAX probabilities as the basis for intervention thresholds. 
Despite effective assessment tools and medications for osteoporosis, screening for fracture 
risk is not currently advocated in many countries, including the UK, although NICE 
recommends assessment of fracture risk in all women aged 65 years and older. A recent 
randomised controlled trial, the SCOOP study, investigated whether community-based 
screening could reduce fractures in women age 70 to 85 years [8]. Fracture risk was evaluated 
for patients randomised to the screening arm using the FRAX tool. If hip fracture probability 
was high, the patient was invited to undergo a dual energy X-ray absorptiometry scan (DXA) to 
measure BMD at the femoral neck. There was no evidence that screening reduced the 
incidence of all osteoporosis-related fractures (HR: 0.94, 95% CI: 0.85 to 1.03) but there was 
strong evidence of a reduction in the risk of hip fractures (HR: 0.72, 95% CI: 0.59 to 0.89). A 
cost-effectiveness analysis based on the SCOOP study, using a within-trial design limited to the 
time frame of the trial (5 years), provided evidence that screening was likely cost‐effective and 
an efficient use of health care resources [9]. 
It is important to analyse the long-term consequences of screening for fracture risk in terms of 
costs and health-related outcomes to inform future decisions about such clinical strategies. 
The objective of this study was to estimate the long-term cost-effectiveness of screening for 








SCOOP (‘screening for prevention of fractures in older women’) was a pragmatic, unblinded, 
two parallel group randomised controlled trial to assess the effectiveness and cost-
effectiveness of screening to prevent fractures in older women [8]. The primary endpoint was 
the proportion of participants experiencing at least one osteoporosis-related fracture over the 
5-year follow-up. Women age 70–85 years were recruited from primary care in seven regions 
in England (Norwich, Southampton, Bristol, Birmingham, Manchester, York and Sheffield). 
Consenting participants were randomised to either a screening arm (n=6,233) or the control 
arm (n=6,250).  
Using a baseline risk factor questionnaire, 10-year hip fracture probability with FRAX was 
calculated for participants randomised to the screening arm. The risk factors included in the 
questionnaire and used to calculate fracture probability were age, sex, height, weight, prior 
fragility fracture, parental history of hip fracture, current smoking, use of oral glucocorticoids, 
rheumatoid arthritis, other causes of secondary osteoporosis and high daily alcohol 
consumption (≥3 units/day). If the hip fracture probability was high (5.2–8.5%, depending on 
age), the participant was invited to undergo a DXA measurement at the femoral neck. Fracture 
probability was then re-calculated with the inclusion of the BMD result, and individuals with a 
fracture risk above the intervention threshold (hip fracture probability between 5.24% and 
8.99% depending on age) were advised to make an appointment with their General 
Practitioner (GP) to discuss potential treatment. The GP was also informed directly of the 
screening result. 
For the participants randomised to the control arm, a letter was sent to the GP informing 
them of their patient’s participation in the study. No additional information was provided to 
these women or their GP and they received standard management. The 10-year fracture 
probability using FRAX was calculated for the control arm participants at the end of the study.  
Characteristics were similar across groups: the mean age was 75.4 years (SD 4.2) in the 
screening arm, and in control arm was 75.5 years (SD 4.1); FRAX 10-year hip fracture 
probability in the screening arm was 8.5% (SD 7.4) and in the control arm was 8.5% (SD 7.3); 
the 10-year probability of a major osteoporotic fracture (distal forearm, clinical spine, 
proximal humerus or hip fracture) was 19.3% in the screening arm (SD 8.9) and 19.3% (SD 8.8) 
in the control arm.  
Screening led to a relative reduction in hip fractures of 28% compared with the control arm 
(HR=0.72, 95% CI 0.59 to 0.89, p=0.002). The proportion of women who experienced an 
osteoporosis-related fracture was similar in the screening arm to the control arm (12.9% vs. 
13.6%, HR 0.94, 95% CI 0.85 to1.03, p=0.178). 
Health economic model 
A health economic Markov model was used to predict the life-time consequences in terms of 
costs and quality of life of the screening programme compared with the control arm 
(hereafter termed usual management). The model was adapted based on previously published 
models of osteoporosis interventions [10-12]. The model used a six-month cycle length and 
the cohort was followed from study participation until death or an age of 100 years. The 
model consisted of eight health states, including: wrist fracture, vertebral fracture, hip 
fracture, other osteoporotic fracture, post-vertebral fracture, post-hip fracture, dead and well 




pelvis, rib, humerus, tibia, clavicle, scapula, sternum and other femoral fractures. Patients who 
sustained a hip/vertebral fracture transitioned to the post hip/vertebral fracture state in the 
cycle following the fracture and remained there until sustaining a new vertebral or 
hip/vertebral fracture or death occurred. All patients began in the “well” health state.  In each 
cycle, an individual was at risk of sustaining a fracture or death (Figure 1).  
 
 
Fig.1 Model structure. Fx = fracture 
Data 
The model was populated with costs related to drugs, administration and screening 
intervention derived from the SCOOP data. Fracture risk reduction in the screening arm 
compared with the usual management arm was derived from SCOOP data. Modelled fracture 
risk corresponded to the risk observed in SCOOP.  
Clinical costs in the first and subsequent years after fracture were collected from two 
retrospective cohort studies that estimated fracture costs in postmenopausal women in the 
UK [13, 14]. In the “Well” health state, quality of life based on EQ-5D-3L was assumed to be 
equal to the age and gender matched general UK population taken from a study by Szende et 
al. [15]. Wrist, hip, vertebral and other fractures were assumed to have an impact on quality 
of life during the first year after fracture (weights 0.82, 0.55, 0.68 and 0.86, respectively). Hip 
and vertebral fractures were assumed to also have an impact on quality of life in subsequent 
years (weights 0.82 and 0.84, respectively). Quality of life weights, in the first year after 
fracture and subsequent years respectively, were collected from the International Costs and 
Utilities Related to Osteoporotic fractures Study (ICUROS) [16]. Annual mortality in the general 
female population was obtained from the Office for National Statistics dataset [17]. The 
relative risks of death in patients who had sustained a fracture compared with the general 
population were derived from a study by Jönsson et al. [12]. In agreement with previous 
health economic studies of osteoporotic treatments it was assumed that 30% of the excess 
mortality after a hip, vertebral, wrist and other osteoporotic fracture was related to the 
fracture event [10]. The remaining excess mortality was assumed to be related to other 





The outcome measures were life years, quality-adjusted life years (QALYs), costs and 
incremental cost per QALY (ICER). Costs and effects were discounted by 3.5% annually in 
accordance with NICE guidelines [20]. The intervention was assumed to be cost-effective if the 
ICER lay at or below NICE’s willingness-to-pay (WTP) threshold for recommending new 
treatment of £20,000–30,000 per QALY gained [20]. 
A probabilistic sensitivity analysis (PSA) was conducted by simultaneously sampling from 
estimated probability distributions of treatment effect of screening vs. usual management to 
obtain 1,000 sets of model input estimates. For each simulation, expected costs and QALYs 
were calculated for the screening arm and the usual management arm, respectively, along 
with the difference between comparators. Acceptability curves were constructed for the 
pairwise comparison.  
Since the SCOOP study only provided evidence of an effect of screening compared with usual 
management for hip fracture risk reduction, a deterministic sensitivity analysis was conducted 
assuming that screening had an effect only on this risk.  
Other deterministic sensitivity analyses were conducted to estimate the impact on the results 
of changing the discount rate, modelling time horizon, and assuming that 100% of the excess 
mortality of fracture was related to the fracture event. 
 
Results 
Base case scenario 
Over the remaining lifetime (mean 14 years) of 1,000 women, screening saved 9 hip fractures 
and 20 non-hip fractures compared with usual management. Fracture-related costs were £551 
lower per patient in the screening arm compared with the usual management arm (Table 1). 
Drug and intervention costs were £265 higher in the screening arm. In total, the screening arm 
was cost-saving (£286) and gained 0.015 QALYs/patient in comparison with usual 
management arm.  
  




Screening Screening vs. usual 
management 
Mean costs, per patient (£) 
   
Hospitalisations 3,059 2,934 -125 
Nursing home 6,056 5,645 -410 
Outpatient 378 363 -15 
Total morbidity cost 9,493 8,942 -551 
    
Drugs 12 43 31 
Treatment management 92 326 234 




    
Total cost 9,596 9,310 -286 
    
Effects, per patient 
   
Life years 10.485 10.487 0.002 
QALYs 7.359 7.374 0.015 










Probabilistic sensitivity analysis (PSA) 
The PSA showed that the probability of screening being cost-effective at a willingness-to-pay 
(WTP) of £20,000 was 97% and 98% at a WTP of £30,000. In 87% of the PSA simulations, 
screening was cost-saving, i.e. saved costs and gained QALYs, compared with usual 
management. Mean difference in QALYs (screening vs. usual management) was 0.015 (95% CI 
0.007, 0.023). Mean difference in costs was £-281 (95% CI -579, -77).  
 
Fig. 2 Cost-effectiveness acceptability curve for pairwise 
comparison of screening vs. no screening. 
 
Deterministic sensitivity analyses 
When it was assumed that screening had an effect only on the risk of hip fracture, the QALY 
gained and cost-savings were lower compared with the base case scenario. However, the 
results showed that screening would still be cost-saving if the programme had an effect on hip 





Table 2 Results of deterministic sensitivity analysis assuming screening had an effect only on 




Screening Screening vs. usual 
management 
Total cost (£), per 
patient 
9,596 9,355 -241 





Other sensitivity analyses 
The impact of changing modelling assumptions on the QALY gained of screening compared 
with usual management is shown in Table 3. In all scenarios, screening was cost-saving (not 
shown in table). The results were most sensitive to assuming a 0% discount rate on effects and 
costs. Results were also rather sensitive to assuming that 100% of excess mortality was 
attributable to fractures. Applying a 10-year time horizon had a small negative impact in this 
population of older women.  
 
Table 3 Other sensitivity analyses 
Scenario QALY difference per patient, 
screening vs. usual management 
Base case 0.015 
5% discount rates 0.014 
0% discount rates 0.020 
10-year modelling time horizon 0.012 





Osteoporosis is a silent disease that tends to go underdiagnosed and undertreated despite the 
availability of effective assessment tools and medications. This study estimated the cost-
effectiveness of screening for hip fracture risk with the FRAX tool compared with usual 
management in UK primary care setting, using a health economic Markov model to estimate 
the life-time consequences of screening. The population modelled and fracture risks were 
based on to the SCOOP study. We found that screening gained 0.015 QALYs and saved £286 
per patient because of fracture risk reduction compared with usual management; the 
conclusions were robust across a number of sensitivity analyses. This study indicates that 
screening for fracture risk in elderly women is an efficient means to identify high risk patients, 
improve treatment uptake in these patients, and ultimately improve health outcomes. 
Our study has a number of strengths and limitations. A major strength is the use of fracture 




of the relative effect of screening based in a real-world setting. The structure of the Markov 
model used in this study is validated and adapted based on a model used in previously 
published studies [12]. A limitation of the model is that it has a hierarchical structure that 
causes a slight underestimation of the number of less severe fractures, as patients suffering a 
hip or vertebral fracture cannot subsequently sustain wrist or other fractures in following 
cycles (i.e. remain in post hip/vertebral state). Some other assumptions were necessary to 
estimate the life-time consequences of screening and usual management. The most 
conservative assumption was that the effect of screening was only modelled for a maximum 
of 5 years, - the follow-up time in the SCOOP study, and thereafter women in the screening 
arm were assumed to be at the same fracture risk as the usual management arm. This 
assumption sets a ceiling on the potential gains as it ignores the fact that many high-risk 
women would continue on treatment for longer than 5 years and that the offset of treatment 
effects is not immediate. Population-based studies show long term reductions in hip fractures 
risk during longer exposures to anti-resorptive medications similar to those used in SCOOP 
[21]. The assumption that the protective effect on fracture risk ceases on the day of 
medication discontinuation is very conservative and further contributes to the ceiling effect. 
Oral bisphosphonates, the predominant treatment prescribed for high risk patients in SCOOP, 
are known to at least partially reduce bone turnover and bone mineral density for several 
months or years following discontinuation [22, 23], with likely persisting fracture protection. 
These observations underpin recent suggestions that patients could undertake a break from 
bisphosphonate therapy without immediately losing fracture protection [24-27]. An 
assumption of a linear offset of the fracture protective effect over a few years has been built 
into previous models of oral bisphosphonate and has a significant impact on improving cost-
effectiveness [28].  
The cost-effectiveness analysis based on the SCOOP study by Turner et al. [9] used, in contrast 
to the analysis in this paper, a within-trial design limited to the time frame of the trial (5 
years). Additionally, it used questionnaires (EQ-5D) ) to document self-reported quality of life 
(QoL) at typically annual intervals to derive QALYs. The results showed that the QALYs per 
person gained with screening was 0.0237 (95% CI: -0.0034 to 0.0508) with an incremental 
total health care cost of £66 (95% CI -21.7, 153) compared with usual management, providing 
a cost per QALY gained of £2,772. This compares with the longer-term gains of 0.015 QALYs 
(95% CI 0.007, 0.023) per person and a £241 (95% CI -579, -77) lower cost yielding a cost-
saving result in the present analysis. The expectation, given the different study designs, would 
be that modelling over a longer time period (remaining lifetime) would provide larger cost-
savings [29]. While we might also expect a larger average QALY gain over a longer timeframe, 
the within-trial analysis showed a larger apparent gain (0.0237 vs. 0.015), despite the QoL 
questionnaires not being administered at the time of the incident fracture events. The reason 
for the difference is not entirely clear. One potential explanation, besides the inherent 
differences in study design between modelling and within-trial analysis, could be that the 
within-trial study design captured an additional element of quality of life improvement 
resulting from screening, an improvement that hasn’t been noted in screening studies in other 
diseases [30, 31]. Alternatively, it could be an effect related to pharmaceutical treatment or 
fracture prevention, but this seems unlikely given the small proportion of patients on 




larger gain in QALYs occurred by chance,  given that SCOOP was not primarily powered to 
detect a statistical difference in QALYs between arms, and indeed there was no evidence of 
such a difference as displayed in the confidence interval around the mean [9]. Disregarding 
the unexpected difference in QALYs gained between the two studies, it is clear that both 
studies used well accepted health economic methods, and both consistently indicate that a 
screening programme of fracture risk is a cost-effective intervention.  
A small number of randomised studies have now addressed the potential benefit of 
population screening for fracture prevention. In the Aberdeen Prospective Osteoporosis 
Screening Study (APOSS), 4,800 women aged 45–54 years were screened by BMD. 
Osteoporosis treatment, predominantly hormone replacement therapy (HRT) was 
recommended to those women with BMD in the lowest quartile of the screening arm. The 
study showed an increase in HRT uptake in those so identified [32], and a parallel increase in 
uptake of other osteoporosis therapies [33]. After a follow-up of 9 years, the study reported 
weak evidence of a decrease in fracture rates in the screened arm, but this did not alter the 
UK National Screening Committee’s position of not recommending screening in osteoporosis 
[34]. The latter decision was underpinned by the conclusion that there was no randomised 
controlled trial assessing the clinical and cost-effectiveness of any current approach to 
screening for osteoporosis. The SCOOP study has now addressed this, and recently another 
study of screening using the FRAX tool has been published from Denmark [35-37]. While no 
formal cost-effectiveness analysis has yet been published from the latter study, the FRAX 
approach in both studies avoids the use of bone mineral density measurements in all 
participants, thus reducing this contribution to screening costs. A systematic review found 
that screen-and-treat strategies based on FRAX and similar tools were more cost-effective 
compared with selecting patients based solely on age, gender and BMD [38]. This may be 
explained by lower screening costs due to avoided BMD measurements, but also that FRAX 
and similar tools enables finding patients where it is cost-effective to treat even at lower ages 
(e.g. 50–60 years). 
 
Conclusion 
The burden of fragility fractures in ageing populations is high and increasing. There is a 
substantial treatment gap so that most women at high risk of fracture are neither identified 
nor treated. This analysis suggests that a screening programme for fracture risk in older 
women in the UK could gain quality of life and life years, and reduce fracture costs so as to 
more than offset the cost of running the programme. 
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